Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The present study is a phase I, single-centre, double-blind, randomized, cross-over (3
treatments, 3 treatment periods and 6 sequences), stratified (background medication:
metformin vs. diet-only), placebo-controlled study, comparing periods lasting 6-9 days on
treatment with repeated doses of vildagliptin, sitagliptin, or placebo, with wash-out periods
between treatment periods lasting 21 days minimum.
The study was designed to directly compare the effects of vildagliptin and sitagliptin on
incretin hormone responses, glycaemia, and insulin as well as glucagon secretory responses in
patients with type 2 diabetes.